Breakthrough in Brain Cancer: Virus Makes Glioblastoma Vulnerable

A Single Injection Opens the Way for the Immune System

Researchers at Mass General Brigham and the Dana-Farber Cancer Institute have achieved a breakthrough in the treatment of glioblastoma using a modified herpes virus. According to their findings, published in the journal Cell in March 2026, a single injection of the virus can penetrate the tumor, destroy cancer cells, and recruit immune cells deep within the tumor.

Glioblastoma is the most aggressive malignant brain tumor: the average survival time from diagnosis is only 12–15 months, and the standard treatment protocol has remained essentially unchanged for twenty years. Immunotherapies, which have yielded revolutionary results in other types of cancer, have consistently failed in the case of glioblastoma because the tumor is extremely effective at suppressing the body's immune response.

How Does the Oncolytic Virus Work?

The new therapy is based on a genetically modified herpes simplex virus designed to replicate exclusively in glioblastoma cells, leaving healthy tissue untouched. When the virus infects a cancer cell, it destroys it, and then its copies spread to neighboring tumor cells. This dual mechanism not only directly kills the cancer but also reprograms the tumor microenvironment, allowing T cells—the immune system's "soldiers"—to enter the tumor's depths.

"Glioblastoma is a notoriously 'cold' tumor, into which anti-cancer immune cells barely penetrate," said Kai Wucherpfennig, head of cancer immunology at Dana-Farber. "We have now proven that it is possible to deliver these critical immune cells into glioblastoma."

Promising Clinical Results

In a Phase 1 clinical trial, 41 patients with recurrent glioblastoma were treated with the modified virus. The results showed that the treatment resulted in longer survival compared to data from previous, similar patient groups. Notably, the effect was strongest in patients who already had antibodies against the herpes virus—meaning that previous exposure to the virus paradoxically became an advantage.

The researchers also showed that cytotoxic T cells persisted in the tumor, and those in whom these immune cells were located closer to the dying tumor cells experienced significantly longer survival.

"Our results may have important implications for a cancer whose treatment standard has not changed in twenty years," said E. Antonio Chiocca, director of the Mass General Brigham Brain Tumor Center.

What Does This Mean for Hungary?

In Hungary, approximately 400 new glioblastoma diagnoses are made each year—this is the most common type of malignant brain tumor. The disease typically affects people in the 55–60 age group, with an even higher incidence in older individuals. Although the current results come from an early-phase study, and widespread application may take years, the breakthrough offers hope to patients and their families suffering from a disease that has been considered virtually incurable.

The next step is to initiate larger, Phase 2 clinical trials that can confirm the therapy's efficacy and safety. The researchers are optimistic: virus-based immunotherapy could usher in a new era in the treatment of brain cancer.